Trial Profile
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, MULTICENTER STUDY OF THE LONG-TERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN JAPANESE ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Dec 2021
Price :
$35
*
At a glance
- Drugs Tanezumab (Primary) ; Celecoxib
- Indications Back pain
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Acronyms TANGO
- Sponsors Pfizer
- 29 Jul 2019 According to a Pfizer media release, results presented in a financial report.
- 12 Jul 2019 Status changed from active, no longer recruiting to completed.
- 03 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2019.